JP7891230B2 - 注意欠陥/多動性障害の治療又は予防に使用するための化合物 - Google Patents

注意欠陥/多動性障害の治療又は予防に使用するための化合物

Info

Publication number
JP7891230B2
JP7891230B2 JP2023546027A JP2023546027A JP7891230B2 JP 7891230 B2 JP7891230 B2 JP 7891230B2 JP 2023546027 A JP2023546027 A JP 2023546027A JP 2023546027 A JP2023546027 A JP 2023546027A JP 7891230 B2 JP7891230 B2 JP 7891230B2
Authority
JP
Japan
Prior art keywords
adhd
composition according
formula
administered
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023546027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508372A5 (cg-RX-API-DMAC7.html
JP2024508372A (ja
Inventor
エーギル カールソン,カール
ソルスタインソン,ハラルドゥル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3Z ehf
Original Assignee
3Z ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2101291.9A external-priority patent/GB202101291D0/en
Priority claimed from GBGB2101296.8A external-priority patent/GB202101296D0/en
Priority claimed from GBGB2101292.7A external-priority patent/GB202101292D0/en
Application filed by 3Z ehf filed Critical 3Z ehf
Publication of JP2024508372A publication Critical patent/JP2024508372A/ja
Publication of JP2024508372A5 publication Critical patent/JP2024508372A5/ja
Application granted granted Critical
Publication of JP7891230B2 publication Critical patent/JP7891230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023546027A 2021-01-29 2022-01-28 注意欠陥/多動性障害の治療又は予防に使用するための化合物 Active JP7891230B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2101291.9A GB202101291D0 (en) 2021-01-29 2021-01-29 Novel treatments
GB2101292.7 2021-01-29
GB2101296.8 2021-01-29
GB2101291.9 2021-01-29
GBGB2101296.8A GB202101296D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101292.7A GB202101292D0 (en) 2021-01-29 2021-01-29 Novel treatments
PCT/EP2022/052142 WO2022162199A2 (en) 2021-01-29 2022-01-28 Novel treatments

Publications (3)

Publication Number Publication Date
JP2024508372A JP2024508372A (ja) 2024-02-27
JP2024508372A5 JP2024508372A5 (cg-RX-API-DMAC7.html) 2025-07-17
JP7891230B2 true JP7891230B2 (ja) 2026-07-16

Family

ID=80682355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546027A Active JP7891230B2 (ja) 2021-01-29 2022-01-28 注意欠陥/多動性障害の治療又は予防に使用するための化合物

Country Status (12)

Country Link
US (2) US20240130995A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284356B1 (cg-RX-API-DMAC7.html)
JP (1) JP7891230B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022215118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206935A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038949T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250747T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071725T2 (cg-RX-API-DMAC7.html)
PL (1) PL4284356T3 (cg-RX-API-DMAC7.html)
RS (1) RS66934B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500238T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022162199A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093748A1 (en) * 2023-11-03 2025-05-08 3Z Pharmaceuticals Use of a calcium channel blocker in the treatment of adhd

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512339A (ja) 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション 記憶障害の処置における(+)−イソプロピル2−メトキシエチル4−(2−クロロ−3−シアノ−フェニル)−1,4−ジヒドロ−2,6−ジメチル−ピリジン−3,5−ジカルボキシラートの使用
US20080226715A1 (en) 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
US20110136793A1 (en) 2008-05-28 2011-06-09 Hoyle Peter C Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
US20150247847A1 (en) 2012-09-11 2015-09-03 Institució Catalana De Recercai Estudis Avançats Diagnostic method for detecting an autoimmune disease and related subject-matter

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1030672A1 (en) * 1997-11-19 2000-08-30 Merck & Co., Inc. Method for treating attention deficit disorder
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
WO2014133329A1 (ko) * 2013-02-27 2014-09-04 에스케이케미칼 주식회사 관절염 치료용 복합 제제
KR20140135676A (ko) * 2014-10-02 2014-11-26 한국과학기술원 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 t―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물
BR112020008371A2 (pt) * 2017-10-27 2020-11-03 Esteve Pharmaceuticals, S.A. novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512339A (ja) 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション 記憶障害の処置における(+)−イソプロピル2−メトキシエチル4−(2−クロロ−3−シアノ−フェニル)−1,4−ジヒドロ−2,6−ジメチル−ピリジン−3,5−ジカルボキシラートの使用
US20080226715A1 (en) 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
US20110136793A1 (en) 2008-05-28 2011-06-09 Hoyle Peter C Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
US20150247847A1 (en) 2012-09-11 2015-09-03 Institució Catalana De Recercai Estudis Avançats Diagnostic method for detecting an autoimmune disease and related subject-matter

Also Published As

Publication number Publication date
EP4284356B1 (en) 2025-04-02
WO2022162199A2 (en) 2022-08-04
JP2024508372A (ja) 2024-02-27
US20240130995A1 (en) 2024-04-25
CA3206935A1 (en) 2022-08-04
EP4284356A2 (en) 2023-12-06
HRP20250747T1 (hr) 2025-08-15
WO2022162199A3 (en) 2022-09-15
HUE071725T2 (hu) 2025-09-28
RS66934B1 (sr) 2025-07-31
EP4284356C0 (en) 2025-04-02
AU2022215118A1 (en) 2023-08-17
AU2022215118A9 (en) 2024-05-16
SMT202500238T1 (it) 2025-07-22
PL4284356T3 (pl) 2025-07-28
ES3038949T3 (en) 2025-10-16
US20260199279A1 (en) 2026-07-16

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260626

R150 Certificate of patent or registration of utility model

Ref document number: 7891230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150